Should patients with systemic sclerosis-related pulmonary arterial hypertension be anticoagulated?

Date

2013

Authors

Nikpour, M.
Stevens, W.
Proudman, S.
Buchbinder, R.
Prior, D.
Zochling, J.
Williams, T.
Gabbay, E.
Nandurkar, H.

Editors

Advisors

Journal Title

Journal ISSN

Volume Title

Type:

Journal article

Citation

Internal Medicine Journal, 2013; 43(5):599-603

Statement of Responsibility

M. Nikpour, W. Stevens, S. M. Proudman, R. Buchbinder, D. Prior, J. Zochling, T. Williams, E. Gabbay and H. Nandurkar

Conference Name

Abstract

Pulmonary arterial hypertension (PAH) is a major cause of mortality in scleroderma and despite ‘advanced’ therapies confers a median survival of less than 5 years. Anticoagulation in systemic sclerosis-related PAH (SSc-PAH) is currently one of the most contentious issues in the management of patients with connective tissue disease. While some studies have shown a survival benefit with warfarin therapy in this disease, others have not. Accordingly, a state of clinical equipoise exists in relation to anticoagulation in SSc-PAH. With an over fivefold reduction in mortality demonstrated in some observational studies, the issue of anticoagulation in SSc-PAH demands resolution through a well-designed randomised controlled trial.

School/Discipline

Dissertation Note

Provenance

Description

Access Status

Rights

© 2013 The Authors

License

Grant ID

Call number

Persistent link to this record